抄録
In 1996, research was conducted at the National Cardiovascular Center to determine prescribing trends for drugs used in the treatment of myocardial infarction (MI). Since much evidence was collected and clinical guidelines for the treatment of MI were established, we thought that the prescribing trends might have changed in the following years so in 2004, we conducted research to determine what changes had occurred in the period from 1996 to 2004. The frequency of prescribing platelet aggregation inhibitors, β-adrenergic antagonists, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARB) was higher in 2004, when platelet aggregation inhibitors were prescribed for 91.6% of the patients with MI, and aspirin was prescribed for 86.4% of the patients. The frequencies of prescribing multiple drugs for ischemic heart disease was high in both 1996 and 2004, and β-adrenergic antagonists had become the predominant drugs in multiple drug therapy in 2004. β1-selective adrenergic antagonists without intrinsic sympathetic activity and αβ-adrenergic antagonists were major drugs among the β-adrenergic antagonists. Among calcium antagonists, the frequency of amlodipine use showed an upward trend in this eight-year period. In conclusion, our findings indicate that standard pharmacotherapy for MI based on the evidence and clinical guidelines has been introduced at NCVC.
